Pursuant to Regulation 30 read with Schedule III to the Securities and Exchange Board of India (Listing Obligation and Disclosure Requirements) Regulation, 2015 (‘Listing Regulations’), Sai Life Sciences has informed that the Board of Directors of the Company has approved and allotted 3,00,000 fully paid-up equity shares of Re.1/ each upon exercise of options granted under MESOP 2018, vide circular resolution dated 23rd July, 2025. The details required under Regulation 10(c) of SEBI (Share Based Employee Benefits and Sweat Equity) Regulations, 2021 are enclosed as Annexure-A. Further, the details required as per SEBI Circular SEBI/HO/CFD/PoD2/CIR/P/0155 dated 11 November 2024 are enclosed as Annexure-B.
The above information is a part of company’s filings submitted to BSE.
